

Substitute PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |    |   |                          |                            |
|--|---|----|---|--------------------------|----------------------------|
| Substitute for form 1449A/PTO<br>(Modified)<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(use as many sheets as necessary) |   |    |   | <b>Complete if Known</b> |                            |
|  |   |    |   | Application Number       | 10/543,122                 |
|  |   |    |   | Filing Date              | January 26, 2004           |
|  |   |    |   | First Named Inventor     | SHENOY, Sudha              |
|  |   |    |   | Art Unit                 | To be assigned             |
|  |   |    |   | Examiner Name            | To be assigned             |
| Sheet  | 1 | of | 3 | Attorney Docket Number   | 186563/US/2 (469390-00352) |

| U.S. PATENT DOCUMENTS |                       |  |                             |   |   |
|-----------------------|-----------------------|--|-----------------------------|---|---|
| Examiner Initials*    | Cite No. <sup>1</sup> | Document Number Number-Kind Code <sup>2</sup> (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|                       | A1                    | US-3,654,090   | 04-04-1972                  | Schuurs   |   |
|                       | A2                    | US-3,850,752   | 11-26-1974                  | Schuurs et al.                                  |   |
|                       | A3                    | US-4,016,043   | 04-05-1977                  | Schuurs et al.                                  |   |
|                       | A4                    | US-4,341,761   | 07-27-1982                  | Ganfield et al.                                 |   |
|                       | A5                    | US-4,399,121   | 08-16-1983                  | Albarella et al.                                |   |
|                       | A6                    | US-4,427,783   | 01-24-1984                  | Newman et al.                                   |   |
|                       | A7                    | US-4,444,887   | 04-24-1984                  | Hoffmann  |   |
|                       | A8                    | US-4,451,570   | 05-29-1984                  | Royston et al.                                  |   |
|                       | A9                    | US-4,466,917   | 08-02-1984                  | Nussenzweig et al.                              |   |
|                       | A10                   | US-4,472,500   | 09-18-1984                  | Milstein et al.                                 |   |
|                       | A11                   | US-4,491,632   | 01-01-1985                  | Wands et al.                                    |   |
|                       | A12                   | US-4,493,795   | 01-15-1985                  | Nestor et al.                                   |   |
|                       | A13                   | US-4,493,890   | 01-15-1985                  | Morris  |   |
|                       | A14                   | US-5,625,048   | 04-29-1997                  | Tsien et al.                                    |   |
|                       | A15                   | US-5,777,079   | 07-07-1998                  | Tsien et al.                                    |   |
|                       | A16                   | US-5,891,646   | 04-06-1999                  | Barak et al.                                    |   |
|                       | A17                   | US-6,066,476   | 05-23-1990                  | Tsien et al.                                    |   |
|                       | A18                   | US-6,110,693   | 08-29-2000                  | Barak et al.                                    |   |
|                       | A19                   | US-RE 31,006   | 08-03-1982                  | Schuurs et al.                                  |   |

| FOREIGN PATENT DOCUMENTS |                       |   |                                |   |   |                |
|--------------------------|-----------------------|---|--------------------------------|---|---|----------------|
| Examiner Initials*       | Cite No. <sup>1</sup> | Foreign Patent Document<br>Country Code <sup>2</sup> Number <sup>3</sup> Kind Code <sup>5</sup><br>(if known) | Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T <sup>6</sup> |
|                          | B1                    |   |                                |   |   |                |

| NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>6</sup> |
|                                 | C1                    | ANGERS, S., et al., "Detection $\beta_2$ -adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET)," <i>Proc. Natl. Acad. Sci. USA</i> 97(7):3684-3689 (Mar. 2000).  |                |

|                    |                  |                 |            |
|--------------------|------------------|-----------------|------------|
| Examiner Signature | /Zachary Howard/ | Date Considered | 04/23/2008 |
|--------------------|------------------|-----------------|------------|

\*EXAMINER: † These references were previously cited in a related application relied upon for an earlier filing date under 35 USC 120 and no copies are submitted in accordance with 37 CFR 1.98(d). Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

4833-9489-7408\1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.H./

Substitute PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |   |                          |                            |
|---|---|----|---|--------------------------|----------------------------|
| Substitute for form 1449A/PTO<br>(Modified)   |   |    |   | <b>Complete if Known</b> |                            |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(use as many sheets as necessary) |   |    |   | Application Number       | 10/543,122                 |
|   |   |    |   | Filing Date              | January 26, 2004           |
|   |   |    |   | First Named Inventor     | SHENOY, Sudha              |
|   |   |    |   | Art Unit                 | To be assigned             |
|   |   |    |   | Examiner Name            | To be assigned             |
| Sheet   | 2 | of | 3 | Attorney Docket Number   | 186563/US/2 (469390-00352) |

| NON PATENT LITERATURE DOCUMENTS |                       |   |  |  |
|---------------------------------|-----------------------|---|--|--|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. |  |  |
|                                 | C2                    | CLAING, A., et al., "β-Arrestin-mediated ADP-ribosylation factor 6 activation and β <sub>2</sub> -adrenergic receptor endocytosis," <i>J. Biol. Chem.</i> 276(45):42509-42513 (Nov. 2001) (first pub'd online 08/30/2001).                                      |  |  |
|                                 | C3                    | CONG, M., et al., "Binding of the β <sub>2</sub> adrenergic receptor to N-ethylmaleimide-sensitive factor regulates receptor recycling," <i>J. Biol. Chem.</i> 276(48):45145-45152 (Nov. 2001) (first pub'd online 09/27/2001).                                 |  |  |
|                                 | C4                    | EDGE, M., et al., "Total synthesis of a human leukocyte interferon gene," <i>Nature</i> 292(5825):756-762 (Aug. 1981).  |  |  |
|                                 | C5                    | GOVERS, R., et al., "Identification of a novel ubiquitin conjugation motif, required for ligand-induced internalization of the growth hormone receptor," <i>EMBO J.</i> 18(1):28-36 (Jan. 1999).  |  |  |
|                                 | C6                    | HERSHKO, A., et al., "The ubiquitin system," <i>Annu. Rev. Biochem.</i> 67:425-479 (1998).  |  |  |
|                                 | C7                    | HICKE, L., et al., "Ubiquitination of a yeast plasma membrane receptor signals its ligand-stimulated endocytosis," <i>Cell</i> 84(2):277-287 (Jan. 1996).   |  |  |
|                                 | C8                    | JAY, E., et al., "Chemical synthesis of a biologically active gene for human immune interferon-γ. Prospect for site-specific mutagenesis and structure- function studies," <i>J. Biol. Chem.</i> 259(10):6311-6317 (May 1984).                                  |  |  |
|                                 | C9                    | KRUPNICK, J., et al., "Arrestin/clathrin interaction. Localization of the clathrin binding domain of nonvisual arrestins to the carboxy terminus," <i>J. Biol. Chem.</i> 272(23):15011-15016 (Jun. 1997).   |  |  |
|                                 | C10                   | LAPORTE, S., et al., "The β <sub>2</sub> -adrenergic receptor/βarrestin complex recruits the clathrin adaptor AP-2 during endocytosis," <i>Proc. Natl. Acad. Sci. USA</i> 96(7):3712-3717 (Mar. 1999).  |  |  |
|                                 | C11                   | LEFKOVITZ, R., "G protein-coupled receptors. III. New roles for receptor kinases and β-arrestins in receptor signaling and desensitization," <i>J. Biol. Chem.</i> 273(30):18677-18680 (Jul. 1998).   |  |  |
|                                 | C12                   | LUTTRELL, L., et al., "β-arrestin-dependent formation of β <sub>2</sub> adrenergic receptor-Src protein kinase complexes," <i>Science</i> 283(5402):655-661 (Jan. 1999).  |  |  |
|                                 | C13                   | LUTTRELL, L., et al., "Activation and targeting of extracellular signal-regulated kinases by β-arrestin scaffolds," <i>Proc. Natl. Acad. Sci. USA</i> 98(5):2449-2454 (Feb. 2001) (first pub'd online 02/20/2001).  |  |  |
|                                 | C14                   | MORI, S., et al., "Identification of an ubiquitin-ligation system for the epidermal-growth-factor receptor-herbimycin A induces <i>in vitro</i> ubiquitination in rabbit-reticulocyte lysate," <i>Eur. J. Biochem.</i> 247(3):1190-1196 (Aug. 1997).            |  |  |
|                                 | C15                   | MORI, S., et al., "Degradation process of ligand-stimulated platelet-derived growth factor β-receptor involves ubiquitin-proteasome proteolytic pathway," <i>J. Biol. Chem.</i> 270(49):29447-29452 (Dec. 1995).  |  |  |
|                                 | C16                   | NAMBIAR, K., et al., "Total synthesis and cloning of a gene coding for the ribonuclease S protein," <i>Science</i> 223(4642):1299 (Mar. 1984).  |  |  |
|                                 | C17                   | NIMAN, H., et al., "Generation of protein-reactive antibodies by short peptides is an event of high frequency: implications for the structural basis of immune recognition," <i>Proc. Natl. Acad. Sci. USA</i> 80(16):4949-4953 (Aug. 1983).                    |  |  |
|                                 | C18                   | NOREN, C., et al., "A general method for site-specific incorporation of unnatural amino acids into proteins," <i>Science</i> 244(4901):182-188 (Apr. 1989).   |  |  |
|                                 | C19                   | OAKLEY, R., et al., "Differential affinities of visual arrestin, βarrestin1, and βarrestin2 for G protein-coupled receptors delineate two major classes of receptors," <i>J. Biol. Chem.</i> 275(22):17201-17210 (Jun. 2000).                                   |  |  |

|                    |                  |                 |            |
|--------------------|------------------|-----------------|------------|
| Examiner Signature | /Zachary Howard/ | Date Considered | 04/23/2008 |
|--------------------|------------------|-----------------|------------|

\*EXAMINER: † These references were previously cited in a related application relied upon for an earlier filing date under 35 USC 120 and no copies are submitted in accordance with 37 CFR 1.98(d). Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

4833-9489-7408\1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.H./

Substitute PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |    |   |                          |                            |
|--|---|----|---|--------------------------|----------------------------|
| Substitute for form 1449A/PTO<br>(Modified)<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(use as many sheets as necessary) |   |    |   | <b>Complete if Known</b> |                            |
|  |   |    |   | Application Number       | 10/543,122                 |
|  |   |    |   | Filing Date              | January 26, 2004           |
|  |   |    |   | First Named Inventor     | SHENOY, Sudha              |
|  |   |    |   | Art Unit                 | To be assigned             |
|  |   |    |   | Examiner Name            | To be assigned             |
| Sheet  | 3 | of | 3 | Attorney Docket Number   | 186563/US/2 (469390-00352) |

| NON PATENT LITERATURE DOCUMENTS |                       |  |  |  |
|---------------------------------|-----------------------|--|--|--|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.                      |  |  |
|                                 | C20                   | OAKLEY, R., et al., "Molecular determinants underlying the formation of stable intracellular G protein-coupled receptor- $\beta$ -arrestin complexes after receptor endocytosis," <i>J. Biol. Chem.</i> 276(22):19452-19460 (Jun. 2001) (first pub'd online 03/09/2001).             |  |  |
|                                 | C21                   | PERRY, S., et al., "Arresting developments in heptahelical receptor signaling and regulation," <i>Trends Cell Biol.</i> 12(3):130-138 (Mar. 2002).   |  |  |
|                                 | C22                   | PHONPHOK, Y., et al., "Stabilization of clathrin coated vesicles by amantadine, tromantadine and other hydrophobic amines," <i>FEBS Lett.</i> 281(1-2):188-190 (Apr. 1991).  |  |  |
|                                 | C23                   | ROTH, A., et al., "Ubiquitination of the yeast a-factor receptor," <i>J. Cell. Biol.</i> 134(3):661-674 (Aug. 1996).   |  |  |
|                                 | C24                   | SHENOY, S., et al., "Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin," <i>Science</i> 294(5545):1307-1313 (Mar. 2001) (first pub'd online 10/04/2001).   |  |  |
|                                 | C25                   | TOHGO, A., et al., " $\beta$ -Arrestin scaffolding of the ERK cascade enhances cytosolic ERK activity but inhibits ERK-mediated transcription following angiotensin AT1a receptor stimulation," <i>J. Biol. Chem.</i> 277(11):9429-9436 (Mar. 2002) (first pub'd online 01/02/2002). |  |  |
|                                 | C26                   | WANG, C., et al., "TAK1 is a ubiquitin-dependent kinase of MKK and IKK," <i>Nature</i> 412(6844):346-351 (Jul. 2001).  |  |  |
|                                 | C27                   | WANG, Y., et al., "Down-regulation of protease-activated receptor-1 is regulated by sorting nexin 1," <i>Mol. Biol. Cell</i> 13(6):1965-1976 (Jun. 2002).  |  |  |
|                                 | C28                   | ZHENG, B., et al., "RGS-PX1, a GAP for Go <sub>s</sub> and sorting nexin in vesicular," <i>Science</i> 294(5548):1939-1942 (Nov. 2001).  |  |  |

|                    |                  |                 |            |
|--------------------|------------------|-----------------|------------|
| Examiner Signature | /Zachary Howard/ | Date Considered | 04/23/2008 |
|--------------------|------------------|-----------------|------------|

\*EXAMINER: † These references were previously cited in a related application relied upon for an earlier filing date under 35 USC 120 and no copies are submitted in accordance with 37 CFR 1.98(d). Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

4833-9489-7408\1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.H./